Ken Griffin’s Citadel bets £300mn against drugmaker GSK

Unlock the editor’s digest in free

FT editor Raula Khalaf selected his favorite stories in this weekly newsletter.

Hedge Fund has made a bet of £ 305 million against Citdelle’s Drug Maker GSKThe biggest short position against the company for more than a decade.

Billionaire Why Griffin’s hedge funds According to the financial behavior authorities compiled by the supplier breakout point, it said on Tuesday that the company entered the net short position with 0.51 percent of the company’s share.

According to the FCA published, any firm against the FTSE1 Pharmaceutical Group in the 21st released a bet for the last time.

GSK’s shares increased by 5 percent last month as Drugmeaker increased its long-term sales forecast and started Byback to a rare £ 2bn stock Early this month. GSK has reported better than expected income for powerful sales of HIV and cancer drugs.

However, the stock has left the rival pharmaceutical companies back, as drugkeeper investors have failed to stimulate the pipeline of new drugs and vaccines, which they need to replace their HIV drugs when they face the petition cliff after decades. In the last five years, shares in GSK have decreased by 15 percent compared to S&P 500 Pharmaceutical Index, which has increased by 45 percent.

GSK chief executive Emma Walmsale has already faced a fight against investors, while the Hedge Fund Eliot Management formed a million billions of pounds at the company in 2021. Eliot asked that Walmsle was the right leader of the company, he did not give a scientific background. It has also stressed to consider techover offers for its consumer health business halion for GSK, Which was later spentThe

JP Morgan’s analysts say the fourth-thymian income and the direction of the 2021 company were “positive”. However, they added: “We believe the market can question a bridal argument three years from the beginning of HIV Patent Cliff, with a fairly thin late -pipeline, still with a fairly thin late -pipeline.” Berkless analysts also said that the share bayback was “unexpected”.

GSK shares were broken in August 2022 when the Heartburn Drug Jantack was sued. But when GSK settled in most cases in October last year, the shares did not return to their previous level.

The company has also suffered unexpected bad news for the two main products. In 2022, GSK withdrew its cancer drug Blanop from the US market, not fulfilling the FDA requirements for an accelerated drug after a trial. After further study, the company is now hoping that the drug will be restarted by the controller by July 2023.

Its vaccine for breathing syndical virus, known as RSV, has dropped in the second half of last year because the US consultant panel has suggested to limit its use unexpectedly.

According to the LCH Investment Data in the hedge fund, Citdelle is the world’s top-parforing hedge fund. There are hundreds of trading teams in the farm who bet on various types of assets, including equity. At the beginning of the year, Citdel operates $ 65BN valuable investors’ capital and increased by 15.1 percent in 2024.

The firm refused to comment as the firm did not discuss its locations. GSK did not immediately respond to any request for comment.